Antibiotic Susceptibility Patterns of Streptococcus agalactiae Isolated from Different Clinical Specimens Research Article
Main Article Content
Abstract
Streptococcus agalactiae, commonly known as Group B Streptococcus (GBS) is a major etiological agent of invasive neonatal infections worldwide and pose a significant threat to pregnant women and immunocompromised adults. Screening in pregnancy helps determine the need for prophylaxis to prevent neonatal transmission. The present study was conducted to study the prevalence and antimicrobial resistance patterns in GBS isolated from various clinical samples collected from Hyderabad, Sindh. Bacterial isolation and identification were done by using cultural, microscopic, and biochemical testing. The serogrouping was performed using PathoDxtra Strep Grouping Kit (Thermo Scientific). Antibiotic sensitivity profiling was carried out using Kirby-Baur Disc diffusion method. Identification using culturing and immunological testing and sero-grouping revealed seven different groups of Streptococci based on Lancefield grouping system. Among them a total of 117 isolates were GBS which were recovered from urine, blood, pus, HVS, Swabs, fluids, and CSF samples. Gender wise distribution of patients from whom the GBS positive samples were collected showed that 46.15% (n=54) samples were from male and 53.85% (n=63) belonged to female patients while all age groups were sensitive to GBS infections with higher frequency in 0-10 years age group. All isolates of GBS were highly sensitive to vancomycin (100%), followed by penicillin and ceftriaxone (99.14%). However, resistance against clindamycin, and erythromycin, was observed with varying patterns of sensitivity against them. Overall data suggested that although the front-line antibiotics are still largely effective for GBS infections, the sporadic cases of antibiotic resistant GBS and the increasing resistance against lincosamides and macrolides could be challenging for public health. Therefore, frequent local surveillance studies are highly recommended.
Article Details
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clinical microbiology reviews. 1998;11(3):497-513.
2. Rubens C, Smith S, Hulse M, Chi E, Van Belle G. Respiratory epithelial cell invasion by group B streptococci. Infection and immunity. 1992;60(12):5157-63.
3. Gibson RL, Lee M, Soderland C, Chi E, Rubens C. Group B streptococci invade endothelial cells: type III capsular polysaccharide attenuates invasion. Infection and immunity. 1993;61(2):478-85.
4. Petca A, Șandru F, Negoiță S, Dumitrașcu MC, Dimcea DA-M, Nedelcu T, et al. Antimicrobial Resistance Profile of Group B Streptococci Colonization in a Sample Population of Pregnant Women from Romania. Microorganisms. 2024;12(2):414.
5. Moore H, Yeoh D, Hughes C, Raby E, Sandaradura I. Aminoglycosides: an update on indications, dosing and monitoring. Australian Prescriber. 2025;48(4):133.
6. Hsu C-Y, Moradkasani S, Suliman M, Uthirapathy S, Zwamel AH, Hjazi A, et al. Global patterns of antibiotic resistance in group B Streptococcus: a systematic review and meta-analysis. Frontiers in Microbiology. 2025;16:1541524.
7. Urooj Su, Bano S, Tunio SA, Memon BA, Abbasi SM, Rajput Z. High Frequency of Gram-negative Bacilli (GNB) Pathogens in Wounds and Other Clinical Specimens: A Grave Public Health Concern. BioScientific Review. 2024;6(2):20-30.
8. Abbasi R, Bano S, Tunio SA, Brohi NA, Siddiqui A. Evaluating the Bacterial Contamination in Used Cosmetic Products: A Potential Threat to Consumer’s Health. Proceedings of the Pakistan Academy of Sciences: B Life and Environmental Sciences. 2024;61(4):363-70.
9. Maka G, Shah S, Bano S, Tunio S. Antibiotic susceptibility profiling of gram-negative bacteria causing upper respiratory tract infections in Hyderabad, Sindh. JLBSR 2020;1:5-12.
10. CLSI. Performance standards for antimicrobial susceptibility testing (35th ed.; CLSI supplement M100). Clinical and Laboratory Standards Institute. 2025.
11. Plainvert C, Hays C, Touak G, Joubrel-Guyot C, Dmytruk N, Frigo A, et al. Multidrug-resistant hypervirulent group B Streptococcus in neonatal invasive infections, France, 2007–2019. Emerging infectious diseases. 2020;26(11):2721.
12. Liu Y, Ai H. Current research update on group B streptococcal infection related to obstetrics and gynecology. Frontiers in Pharmacology. 2024;15:1395673.
13. Alemayehu G, Geteneh A, Dessale M, Ayalew E, Demeke G, Reta A, et al. High prevalence of penicillin-resistant group B Streptococcus among pregnant women in Northwest Ethiopia. Scientific Reports. 2025;15(1):30047.
14. McGuire E, Ready D, Ellaby N, Potterill I, Pike R, Hopkins K, et al. A case of penicillin-resistant group B Streptococcus isolated from a patient in the UK. Journal of Antimicrobial Chemotherapy. 2025;80(2):399-404.
15. Boyanov V, Alexandrova A, Gergova R. Genetic Mechanisms of Antimicrobial Non-Susceptibility to Novel Fluoroquinolone Delafloxacin Among Bulgarian Clinical Isolates of Streptococcus agalactiae. Current Issues in Molecular Biology. 2025;47(6):446.
16. Li Y, Yang W, Li Y, Hua K, Zhao Y, Wang T, et al. The increasing burden of group B Streptococcus from 2013 to 2023: a retrospective cohort study in Beijing, China. Microbiology Spectrum. 2025;13(1):e02266-24.
17. Coggins SA, Puopolo KM. Neonatal group B Streptococcus disease. Pediatrics in review. 2024;45(2):63-73.